Eli Lilly and Company (LLY) is out today with a much-needed qualifier regarding the emergent probability of its breakthrough GLP-1 weight loss treatments ending up as "lifestyle drugs of choice." To wit, Eli Lilly and Company has now published an open letter, noting among other things: "Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss." While addressing the emerging issues with off-label Tirzepatide-based cocktails, Eli Lilly and Company writes: "Lilly is extremely concerned that some of the compounded Tirzepatide that Lilly has […]
Read full article at https://wccftech.com/eli-lilly-and-company-lly-comes-out-against-the-use-of-glp-1-drugs-for-cosmetic-weight-loss-as-obesity-in-the-us-remains-near-record-highs/
WccftechContinue reading/original-link]